---
layout: default
title: Ambroxol Hcl
parent: 僅模型預測 (L5)
nav_order: 51
evidence_level: L5
indication_count: 0
---

# Ambroxol Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ambroxol HCl: Repurposing Evaluation — Pending TxGNN Prediction Data

## One-Sentence Summary

Ambroxol HCl is a well-established mucolytic and expectorant agent used for respiratory conditions involving abnormal or excessive mucus secretion.
This Evidence Pack does not contain TxGNN model prediction results — no new indication target has been identified for evaluation at this time.
The overall assessment is currently on **Hold**, pending completion of the prediction pipeline and supplementation of critical data gaps.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Respiratory diseases with excessive or viscous mucus (e.g., bronchitis, COPD) |
| Predicted New Indication | Not available — TxGNN prediction not yet performed |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (no actual studies retrievable; model prediction absent) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction results are included in this Evidence Pack (`predicted_indications` is empty). A mechanistic justification for any specific new indication cannot therefore be provided at this stage.

For background context: ambroxol HCl is the active metabolite of bromhexine. It works by stimulating surfactant synthesis in type II pneumocytes, promoting serous secretion in bronchial glands, and enhancing mucociliary clearance — mechanisms that are well-characterised in the management of obstructive and inflammatory airway diseases.

Beyond its classical mucolytic role, published literature has investigated ambroxol as a **pharmacological chaperone for glucocerebrosidase (GBA1)**, giving rise to interest in lysosomal storage disorders and Parkinson's disease in carriers of GBA1 mutations. There is also preclinical evidence suggesting local anaesthetic and anti-inflammatory properties. These directions represent plausible repurposing hypotheses, but cannot be formally evaluated here without TxGNN scores and a structured evidence package.

---

## Clinical Trial Evidence

Currently no related clinical trials are available in this Evidence Pack.

---

## Literature Evidence

Currently no related literature is available in this Evidence Pack.

---

## Malaysia Market Information

One registration is recorded in the Malaysia (NPRA) database; however, the detailed authorization record was not retrieved in this Evidence Pack.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|---------------------|
| — | — | — | Details not retrieved |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack contains no TxGNN prediction results and no clinical evidence, making it impossible to identify or evaluate a repurposing target. Evaluation cannot proceed until the prediction pipeline is completed and mandatory data gaps are resolved.

**To proceed, the following is needed:**

- **Run TxGNN prediction pipeline** for Ambroxol HCl to generate ranked repurposing candidates
- **Retrieve NPRA registration details** (license number, product name, dosage form, approved indication text) — the current record contains empty fields despite recording 1 licence
- **Obtain DrugBank ID and MOA** — DrugBank ID is null; querying the DrugBank API is the recommended remediation
- **Download and parse the package insert PDF** from the Malaysia NPRA portal to populate safety warnings and contraindications (currently blocking further safety screening)
- **Re-run evidence collection** (ClinicalTrials.gov, PubMed) once a target indication is confirmed from the prediction output

> ⚠️ *This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

